| NCT ID | NCT03611738 |
| Title | Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | yes |
| Sponsors | H. Lee Moffitt Cancer Center and Research Institute |
| Indications | |
| Therapies | |
| Age Groups: | adult senior |